NEJM: Risk of New Coronary Pneumonia and Multisystem Inflammation Syndrome in Children

Given the clinical and public health implications ofchildrenmulti-system inflammatory syndrome (MIS-C), it is important to understand its time-to-time correlation with covid-19 in 2019researchers conducted targeted monitoring of MIS-C at pediatric health centers across the United States from March 15 to May 20, 2020MIS-C cases include six criteria: serious illness that causes hospitalization, fever under 21 years of age, fever lasting at least 24 hours, evidence of inflammation in the laboratory, multi-system organ exhaustion, andevidence of SARS-CoV-2 infectiona total of 186 cases of MIS-C were reported in 26states, with a median age of 8.3 years, 115 (62%) boys, 135 (73%) in former health and 131 (70%) positive for SARS-CoV-2 through RT-PCR or antibody164 (88%) of patients hospitalized after 16 April 2020The organ system was affected by 171 cases (92%), 149 cases ofcardiovascular(80%), 142 cases of blood system (76%), 137 cases of skin mucosa (74%), and 131 cases of respiratory system (70%)The median length of stay in hospital is 7 days148 patients (80 per cent) were in intensive care, 37 (20 per cent) received mechanical ventilation, 90 (48 per cent) received vascular-active drugs and 4 (2 per cent) diedRecorded 15 cases (8%) of coronary aneurysms, 74 cases of Kawasaki disease (40%)Most patients (171 cases (92%) have at least four inflammatory biomarkers elevated General use of immuno
regulatory therapy: intravenous immunoglobulin 144 cases (77%), glucocorticoids 91 cases (49%), leukocytele interleukin 6 or 1RA inhibitors 38 cases (20%) study suggests that new coronary pneumonia infection sedifted to an increased incidence of multi-system inflammatory syndrome in children across the United States, and many children and adolescents with previous health to develop serious life-threatening diseases